Effectiveness of Port Site Bupivacaine Injection in Postoperative Pain Reduction After Lap. Chole
NCT ID: NCT05264805
Last Updated: 2022-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
166 participants
INTERVENTIONAL
2022-03-31
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Local Infiltration With Ropivacaine Improves Postoperative Pain Control in Patients
NCT02649179
To Evaluate the Effect of Wound Infiltration With Bupivacaine for Post-operative Pain Relief After Laparoscopic Cholecystectomy
NCT03958513
The Effect of Intraperitoneal Bupivacaine Versus Bupivacaine With Neostigmine on Pain in Laparoscopic Cholecystectomy
NCT04244097
Dexmetomidine With Erector Spinae Plane Block in Cholecystectomy
NCT05369468
Comparison of Efficacy of Bupivacaine for Relief Postoperative Pain in Women Undergoing Laparoscopic Gynecologic Surgery
NCT03259243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Study group: Patient receiving intervention i.e 20ml of 0.25% buvivacaine infiltration at laparoscopic port site.
Group B:
Control group: no intervention
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bupivacaine group
Patient receiving 20ml of inj. 0.25% Bupivacaine at laparoscopic port site
0.25% Bupivacaine
20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
Placebo group
No drug infiltration at laparoscopic port site
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.25% Bupivacaine
20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients undergoing elective laparoscopic cholecystectomy under general anesthesia.
3. Patients with A.S.A grade I and II.
Exclusion Criteria
2. Patients converted to open procedure.
3. Patients developing intra-operative complications.
4. Patients undergoing for laparoscopic cholecystectomy for acute cholecystitis.
5. Patients with obesity and chronic illness.
6. Patients with history of opioids, steroids, NSAIDs and alcohol use.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hamdard University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Nida Shahid
Assistant Professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N0333
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.